Biomarkers-in-Cardiology 8 RE-VISITED—Consistent Safety of Early Discharge with a Dual Marker Strategy Combining a Normal hs-cTnT with a Normal Copeptin in Low-to-Intermediate Risk Patients with Suspected Acute Coronary Syndrome—A Secondary Analysis of the Randomized Biomarkers-in-Cardiology 8 Trial

Regarding the management of suspected Non-ST-segment-elevation acute coronary syndrome (ACS), the main Biomarker-in-Cardiology (BIC)-8 randomized controlled trial study had reported non-inferiority for the incidence of major adverse cardiac events at 30 days in the Copeptin group (dual marker strate...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannitsis, Evangelos, Garfias-Veitl, Tania, Slagman, Anna, Searle, Julia, Müller, Christian, Blankenberg, Stefan, von Haehling, Stephan, Katus, Hugo A., Hamm, Christian W., Huber, Kurt, Vollert, Jörn O., Möckel, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773592/
https://www.ncbi.nlm.nih.gov/pubmed/35053326
http://dx.doi.org/10.3390/cells11020211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773592/
https://www.ncbi.nlm.nih.gov/pubmed/35053326
http://dx.doi.org/10.3390/cells11020211

Ejemplares similares